Pharma Stocks
-
Aurobindo Pharma Sees Notable Surge in Derivatives Open Interest Amid Mixed Market Signals
Open Interest and Volume Dynamics Data from the latest trading sessions reveal that Aurobindo Pharma’s open interest (OI) in derivatives…
Read More » -
Annexin Pharmaceuticals AB (publ)’s (STO:ANNX) Shift From Loss To Profit
Annexin Pharmaceuticals AB (publ) (STO:ANNX) is possibly approaching a major achievement in its business, so we would like to shine…
Read More » -
How Completion of REVITALYZ Enrollment and Orphan Status at Avadel Pharmaceuticals (AVDL) Has Changed Its Investment Story
Avadel Pharmaceuticals has completed patient enrollment in REVITALYZ, its Phase 3 trial testing once-at-bedtime LUMRYZ for idiopathic hypersomnia, advancing the…
Read More » -
London Equities Respond to FTSE 100 as Pharma and Energy Stocks Remain in Focus
Disclaimer The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos,…
Read More » -
Assessing Alumis (ALMS) Valuation After S&P Pharma Index Inclusion and Reinforced Analyst Optimism
Alumis (ALMS) just cleared an important milestone: it has been added to the S&P Pharmaceuticals Select Industry Index, a move…
Read More » -
Sun Pharmaceutical and 5 other pharma stocks with high R&D spending in Q2FY26
Synopsis: 5 of the best Indian Pharmaceutical companies have invested more than 2300crs just in the latest quarter of Q2FY26,…
Read More » -
Is InnoCare Pharma (SEHK:9969) Quietly Recasting Its Future Around Autoimmune Dermatology?
Earlier this month, InnoCare Pharma received CDE approval in China to begin a Phase II/III trial of its novel TYK2…
Read More » -
Aurobindo Pharma Limited (NSE:AUROPHARMA) Shares Could Be 27% Above Their Intrinsic Value Estimate
Key Insights Aurobindo Pharma’s estimated fair value is ₹968 based on 2 Stage Free Cash Flow to Equity Aurobindo Pharma’s…
Read More » -
can a battered pharma giant finally turn the corner?
Bayer AG stock has swung sharply after legal overhangs, restructuring and pipeline questions kept pressure on the share price. Is…
Read More » -
Evoke Pharma Leads Six-Month Stock Performance with 303.23% Return
Over the past six months, several stocks have shown remarkable performance, particularly in the Micro Cap and Small Cap categories.…
Read More »